ES2138976T3 - Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos. - Google Patents

Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.

Info

Publication number
ES2138976T3
ES2138976T3 ES92917650T ES92917650T ES2138976T3 ES 2138976 T3 ES2138976 T3 ES 2138976T3 ES 92917650 T ES92917650 T ES 92917650T ES 92917650 T ES92917650 T ES 92917650T ES 2138976 T3 ES2138976 T3 ES 2138976T3
Authority
ES
Spain
Prior art keywords
interleukin
antagonists
analogs
induced toxicity
treat endotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917650T
Other languages
English (en)
Inventor
Waal Malefyt Rene De
Maureen Howard
Di-Hwei Hsu
Hiroshi Ishida
Anne O'garra
Hergen Spits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2138976T3 publication Critical patent/ES2138976T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)

Abstract

SE PRESENTA UN METODO PARA EL TRATAMIENTO DE CONMOCIONES SEPTICAS O CONMOCIONES TOXICAS QUE CONSISTE EN ADMINISTRAR UNA CANTIDAD EFECTIVA DE INTERLEUCINA-10.
ES92917650T 1991-08-06 1992-08-06 Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos. Expired - Lifetime ES2138976T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74212991A 1991-08-06 1991-08-06

Publications (1)

Publication Number Publication Date
ES2138976T3 true ES2138976T3 (es) 2000-02-01

Family

ID=24983602

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917650T Expired - Lifetime ES2138976T3 (es) 1991-08-06 1992-08-06 Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.

Country Status (17)

Country Link
EP (2) EP0541214A3 (es)
JP (3) JPH07502019A (es)
KR (1) KR100271197B1 (es)
AT (1) ATE187336T1 (es)
AU (1) AU678137B2 (es)
CA (1) CA2115060C (es)
CZ (1) CZ281796B6 (es)
DE (1) DE69230403T2 (es)
DK (1) DK0600970T3 (es)
ES (1) ES2138976T3 (es)
FI (1) FI940519A (es)
GR (1) GR3032167T3 (es)
HU (1) HU224437B1 (es)
NO (1) NO315409B1 (es)
PT (1) PT600970E (es)
SK (1) SK282947B6 (es)
WO (1) WO1993002693A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018783A1 (en) * 1992-03-20 1993-09-30 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
JPH08501549A (ja) * 1992-09-18 1996-02-20 スケアリング コーポレイション Ｈｉｖ感染された患者におけるｔヘルパー細胞の免疫担当能力の回復
JPH08510719A (ja) * 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用
CZ23396A3 (en) * 1993-07-26 1996-05-15 Schering Corp Antagonists and agonists of human interleukin-10
RU2218348C2 (ru) * 1994-07-05 2003-12-10 Стено Рисерч Груп А/С Полипептид с il-10 подобными свойствами (варианты), конъюгат полипептида, фармацевтическая композиция, способ модуляции иммунного ответа у млекопитающего
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
WO2002066069A1 (fr) * 2001-02-20 2002-08-29 Kansai Technology Licensing Organization Co., Ltd. Remedes contre l'inflammation/les maladies tumorales
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
US8956607B2 (en) 2009-11-30 2015-02-17 Biotest Ag Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE)
WO2014147101A1 (en) 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Specific detection of rat antibodies in mouse serum

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
WO1991009127A1 (en) * 1989-12-20 1991-06-27 Schering Corporation BCRF1 PROTEINS AS INHIBITORS OF INTERFERON-$g(g)

Also Published As

Publication number Publication date
NO940370D0 (no) 1994-02-04
NO315409B1 (no) 2003-09-01
FI940519A0 (fi) 1994-02-04
SK12994A3 (en) 1994-12-07
CZ24394A3 (en) 1995-01-18
EP0541214A3 (en) 1993-09-08
HUT66865A (en) 1995-01-30
AU678137B2 (en) 1997-05-22
DK0600970T3 (da) 2000-05-29
DE69230403D1 (de) 2000-01-13
SK282947B6 (sk) 2003-01-09
GR3032167T3 (en) 2000-04-27
JPH07502019A (ja) 1995-03-02
PT600970E (pt) 2000-05-31
FI940519A (fi) 1994-02-04
HU224437B1 (hu) 2005-09-28
JP2004250454A (ja) 2004-09-09
WO1993002693A3 (en) 1993-07-22
ATE187336T1 (de) 1999-12-15
EP0541214A2 (en) 1993-05-12
CZ281796B6 (cs) 1997-02-12
DE69230403T2 (de) 2000-05-11
KR100271197B1 (ko) 2000-11-01
CA2115060A1 (en) 1993-02-18
HU9400314D0 (en) 1994-05-30
EP0600970A1 (en) 1994-06-15
WO1993002693A2 (en) 1993-02-18
EP0600970B1 (en) 1999-12-08
NO940370L (no) 1994-02-04
JP2008013573A (ja) 2008-01-24
AU2441192A (en) 1993-03-02
CA2115060C (en) 2003-05-06

Similar Documents

Publication Publication Date Title
ES2138976T3 (es) Uso de analogos o antagonistas de interleucina-10 para tratar la toxicidad inducida por endotoxinas o superantigenos.
DK0468054T3 (da) Benzensulfonamidderivat
PT98291A (pt) Processo para a preparacao de composicoes farmaceuticas contendo flupirtina para combater distensoes musculares
GB8929076D0 (en) Treatment of shock by blocking agents of edrf effect or formation
PT92752A (pt) Processo para a preparacao de benzilideno-azolilmetilcicloalcanos ou alcenos e de composicoes fungicidas que os contem
BG60249B1 (bg) Тиазолово съединение за лечение на язви
SE8701605D0 (sv) Novel medicinal compounds
ATE143396T1 (de) Dehalogenierung von organohalogen enthaltenden verbindungen
FI933193A0 (fi) Behandling av neoplastisk sjukdom med interleukin-10
DK0536036T3 (da) Tocoferol-analoger med cardioprotektiv virkning.
MX9401175A (es) Inhibidores de la acetilcolinesterasa sililada.
PT545511E (pt) Processo para a preparacao de tetraazamacrociclos mono-n-substituidos
ES2181702T3 (es) Derivados de melatonina para su uso en el tratamiento de enfermedad es del sueño.
PT656209E (pt) Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao
ES2090530T3 (es) Produccion de peces mejorada.
KR950700084A (ko) 소양증 치료제(antipruritic)
ES2106294T3 (es) Uso de disulfonil metanos para el control de parasitos.
BR9307121A (pt) Ferramenta para o tratamento de superfícies de componentes
PE73099A1 (es) Utilizacion de las heparinas de bajo peso molecular para la prevencion y el tratamiento de los edemas cerebrales
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 600970

Country of ref document: ES